Table 1.
Characteristics of the patients included in the study
| Mean (±SD) | N (%) | Median | IQR | Min | Max | |
|---|---|---|---|---|---|---|
| Age | 80.8 (8.3) | 81 | 13 | 57 | 102 | |
| Female | 455 (56.3) | |||||
| N medications | 6.9 (3.8) | 6 | 5 | 0 | 25 | |
| N comorbidities | 8.8 (3.3) | 9 | 5 | 1 | 23 | |
| CTAS (1–5) | 2.6 (0.6) | 3 | 1 | 1 | 5 | |
| CTAS groups | ||||||
| High acuity (CTAS:1–2)a | 307 (38.1) | |||||
| Low acuity (CTAS:3–5)a | 499 (61.9) | |||||
| FI-CGA (0–1) | 0.44 (0.14) | 0.45 | 0.21 | 0.04 | 0.79 | |
| FI-CGA groups | ||||||
| FI-CGA:0–0.2a | 44 (5.5) | |||||
| FI-CGA:0.2–0.3 | 82 (10.2) | |||||
| FI-CGA:0.3–0.4 | 164 (20.4) | |||||
| FI-CGA:0.4–0.5 | 216 (26.9) | |||||
| FI-CGA:0.5–0.6 | 178 (22.1) | |||||
| FI-CGA:0.6+a | 118 (14.7) | |||||
| CFS (1–9) | 5.6 (1.6) | 5 | 1 | 1 | 9 | |
| CFS groups | ||||||
| Fit and well (1–3)a | 78 (9.7) | |||||
| Very mildly frail (4) | 113 (13.9) | |||||
| Mildly frail (5) | 218 (26.9) | |||||
| Moderately frail (6) | 207 (25.6) | |||||
| Severely frail (7) | 85 (10.6) | |||||
| Very severely frail (8) | 38 (4.7) | |||||
| Terminally ill (9) | 69 (8.5) | |||||
| 30-day mortality | 139 (17.2) | |||||
| 6-month mortality | 276 (34.2) |
aCombined due to low sample size.